Goldman Sachs
ABMD

Goldman Sachs’s Abiomed Inc ABMD Stock Holding History

Goldman Sachs’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,300
Closed -$2.61M – 5653
2019
Q4 		$2.61M Buy
+15,300
New +$2.84M ﹤0.01% 3461
2018
Q4 		– Sell
-3,700
Closed -$1.66M – 5808
2018
Q3 		$1.66M Buy
+3,700
New +$1.46M ﹤0.01% 3726
2014
Q1 		– Sell
-46,200
Closed -$1.24M – 6976
2013
Q4 		$1.24M Sell
46,200
-25,800
-36% -$638K ﹤0.01% 4546
2013
Q3 		$1.37M Buy
+72,000
New +$1.65M ﹤0.01% 4297

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's ABMD Position: Q4 2022 in Review

Goldman Sachs sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 127,056 shares — an estimated $31.2M sold.

Goldman Sachs first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $210M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Goldman Sachs reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 127,056 Abiomed Inc shares in Q4 2022, an estimated $31.2M.
  • Goldman Sachs first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Goldman Sachs's Abiomed Inc position peaked at $210M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.